Y-mAbs to Participate in Upcoming Investor Conferences in September
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Pharmaceutical
Avenue Therapeutics to Participate in Upcoming Investor Conferences
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...
Better Choice Company Signs Definitive Agreement to Acquire SRx Health for Approximately $125 Million
Combined company will emerge as a leading global health and wellness company by providing products and solutions for families to...
QL Biopharm Announces Abstract on Novel Ultra Long-acting GLP-1RA to be Presented at EASD Annual Meeting 2024
– Abstract on data from a two-part phase 1c, multiple ascending dose study accepted for oral presentation – – New...
iZafe Group Introduces a Groundbreaking Tripartite Collaboration Aimed at Enhancing Independence and Safety in Medical Care
STOCKHOLM, SWEDEN / ACCESSWIRE / September 3, 2024 / iZafe Group (STO:IZAFE-B.ST) iZafe Group AB ("iZafe Group") today announces a...
Evotec Announces Change in Management Board
Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024Distribution of responsibilities across other Management Board functions...
Health Kiosk Market Surges to USD 3.29 Billion by 2030, Propelled by 12.17% CAGR – Verified Market Reports®
The global Health Kiosk Market is driven by a combination of technological advancements, increasing healthcare awareness, and the rising demand...
Referral Management Market is expected to generate a revenue of USD 13.48 Billion by 2031, Globally, at 15.8% CAGR: Verified Market Research®
The Referral Management Market is driven by the increasing demand for coordinated patient care, the rising adoption of digital healthcare...
Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor
NANJING, China, Sept. 2, 2024 /PRNewswire/ -- On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group...
Hemogenyx Pharmaceuticals PLC Announces CDX Development Update
CDX Development Update LONDON, UNITED KINGDOM / ACCESSWIRE / September 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)("Hemogenyx Pharmaceuticals" or the...
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
GENEVA, SWITZERLAND / ACCESSWIRE / September 2, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical...
Cosmo Pharmaceuticals Highlights Study Published in “The Lancet” Demonstrating the Efficacy of GI Genius(TM) in Colonoscopy Procedures
Dublin, Ireland--(Newsfile Corp. - September 2, 2024) - Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V....
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest...
Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024
Data from Integrated Safety Analysis Across Three Clinical TrialsReinforces Robust Safety Profile of Aficamten Analysis from FOREST-HCM Demonstrates Successful Withdrawal...
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodelingby Cardiac MRI, Improvements in Cardiac Structure and Function by Echocardiography,Symptom Relief and...
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at...
Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
SHANGHAI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading...
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML...
Receipt of Nasdaq Delisting Determination – Plans to Appeal
August 30, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)Receipt of Nasdaq Delisting Determination Plans to Appeal Biodexa Pharmaceuticals PLC (Nasdaq:...
Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Rakovina...